January 17, 2018

Syndax, Genentech to Test Combo Therapy for HR-positive, HER2-negative Metastatic Breast Cancer

News

An upcoming Phase 1b/2 trial will evaluate Syndax Pharmaceuticals‘ investigational therapy entinostat in combination with Genentech‘s Tecentriq (atezolizumab) in women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative ... Read more

October 13, 2017

First Breast Cancer Patient in Japanese Trial Receives Entinostat

News

The first patient has been dosed in a pivotal Phase 2 clinical trial in Japan evaluating entinostat as a therapy for hard-to-treat breast cancers. Syndax Pharmaceuticals, which developed the therapy, said the trial (NCT03291886) ... Read more